Abstract
The concept of a closed-loop, automated insulin delivery system, with continuous glucose sensing and insulin delivery informed by a control algorithm without patient intervention, offers the potential to decrease the burden of diabetes management and modify the significant glycemic excursions associated with conventional therapy. Closed-loop technology represents a change in the treatment paradigm for diabetes as the transition is made from primarily self-management behaviors to automated insulin therapy, potentially relieving the burden and guilt of suboptimal glucose control. The advances in this field have been rapid, and clinical trials are currently underway worldwide testing several systems in various stages of development. We have moved rapidly from inpatient research centers to supervised outpatient settings such as diabetes camps, hotels, and now to the home environment with and without remote monitoring. Recent studies and the potential impact on the care of children with type 1 diabetes are presented in this report.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Wood JR, Miller KM, Maahs DM, et al. Most youth with type 1 diabetes in the T1D exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes Clinical Guidelines. Diabetes Care. 2013;36:2035–7.
Cengiz E, Xing D, Wong JC, et al. Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D Exchange clinic registry. Pediatr Diabetes. 2013;14:447–54.
Campbell MS, Schatz DA, Chen V, et al. A contrast between children and adolescents with excellent and poor control: the T1D exchange clinic registry experience. Pediatr Diabetes. 2014;15:110–7.
Rachmiel M, Landau Z, Boaz M, et al. The use of continuous glucose monitoring systems in a pediatric population with type 1 diabetes mellitus in real-life settings: the AWeSoMe Study Group experience. Acta Diabetol. 2014;52:323–9.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Tamborlane WV, Beck RW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359:1464–76.
Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ. 2011;343:d3805.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Prolonged nocturnal hypoglycemia is common during 12 months of continuous glucose monitoring in children and adults with type 1 diabetes. Diabetes Care. 2010;33:1004–8.
Buckingham B, Block J, Burdick J, et al. Response to nocturnal alarms using a real-time glucose sensor. Diabetes Technol Ther. 2005;7:440–7.
Ly TT, Jones TW, Griffiths A, et al. Hypoglycemia does not change the threshold for arousal from sleep in adolescents with type 1 diabetes. Diabetes Technol Ther. 2011;14:101–4.
Matuleviciene V, Joseph JI, Andelin M, et al. A clinical trial of the accuracy and treatment experience of the Dexcom G4 Sensor (Dexcom G4 System) and Enlite Sensor (Guardian REAL-Time System) tested simultaneously in ambulatory patients with type 1 diabetes. Diabetes Technol Ther. 2014;16:759–67.
Ly TT, Nicholas JA, Retterath A, Davis EA, Jones TW. Analysis of glucose responses to automated insulin suspension with sensor-augmented pump therapy. Diabetes Care. 2012;35:1462–5.
•• Ly TT, Nicholas JA, Retterath A, Lim EM, Davis EA, Jones TW. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA. 2013;310:1240–7. This report showed a reduction in severe hypoglycemia in patients with impaired awareness of hypoglycemia who used sensor-augmented pump with automated insulin suspension.
Buckingham B, Chase HP, Dassau E, et al. Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Care. 2010;33:1013–7.
Maahs DM, Calhoun P, Buckingham BA, et al. A randomized trial of a home system to reduce nocturnal hypoglycemia in type 1 diabetes. Diabetes Care. 2014;37:1885–91.
Hovorka R, Allen JM, Elleri D, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet. 2010;375:743–51.
Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care. 2008;31:934–9.
Kovatchev B, Cobelli C, Renard E, et al. Multinational study of subcutaneous model-predictive closed-loop control in type 1 diabetes mellitus: summary of the results. J Diabetes Sci Technol. 2010;4:1374–81.
Hovorka R, Kumareswaran K, Harris J, et al. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. BMJ. 2011;342:d1855.
O’Grady MJ, Retterath AR, Keenan DB, et al. The use of an automated, portable glucose control system for overnight glucose control in adolescents and young adults with type 1 diabetes. Diabetes Care. 2012;35:2182–7.
Kovatchev BP, Renard E, Cobelli C, et al. Feasibility of outpatient fully integrated closed-loop control: first studies of wearable artificial pancreas. Diabetes Care. 2013;36:1851–8.
Breton M, Farret A, Bruttomesso D, et al. Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia. Diabetes. 2012;61:2230–7.
Grosman B, Dassau E, Zisser HC, Jovanovic L, Doyle FJ 3rd. Zone model predictive control: a strategy to minimize hyper- and hypoglycemic events. J Diabetes Sci Technol. 2010;4:961–75.
Davis EA, Keating B, Byrne GC, Russell M, Jones TW. Hypoglycemia: incidence and clinical predictors in a large population-based sample of children and adolescents with IDDM. Diabetes Care. 1997;20:22–5.
Ly TT, Breton MD, Keith-Hynes P, et al. Overnight glucose control with an automated, unified safety system in children and adolescents with type 1 diabetes at diabetes camp. Diabetes Care. 2014;37:2310–6.
Swan KL, Weinzimer SA, Dziura JD, et al. Effect of puberty on the pharmacodynamic and pharmacokinetic properties of insulin pump therapy in youth with type 1 diabetes. Diabetes Care. 2008;31:44–6.
• Ly TT, Breton MD, Keith-Hynes P, et al. Overnight glucose control with an automated, unified safety system in children and adolescents with type 1 diabetes at diabetes camp. Diabetes Care. 2014;37:2310–6. This report describes overnight closed-loop control using the DIAS system with the Unified Safety System in adolescents with type 1 diabetes in a diabetes camp setting.
Place J, Robert A, Ben Brahim N, et al. DiAs web monitoring: a real-time remote monitoring system designed for artificial pancreas outpatient trials. J Diabetes Sci Technol. 2013;7:9.
Elleri D, Allen JM, Kumareswaran K, et al. Closed-loop basal insulin delivery over 36 hours in adolescents with type 1 diabetes: randomized clinical trial. Diabetes Care. 2013;36:838–44.
Murphy HR, Kumareswaran K, Elleri D, et al. Safety and efficacy of 24-h closed-loop insulin delivery in well-controlled pregnant women with type 1 diabetes: a randomized crossover case series. Diabetes Care. 2011;34:2527–9.
•• Thabit H, Lubina-Solomon A, Stadler M, et al. Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study. Lancet Diabetes Endocrinol. 2014;2:701–9. This paper describes overnight closed-loop control with the Florence automated system with model predictive control algorithm in 24 adults for 4 weeks at home.
•• Hovorka R, Elleri D, Thabit H, et al. Overnight closed-loop insulin delivery in young people with type 1 diabetes: a free-living, randomized clinical trial. Diabetes Care. 2014;37:1204–11. This paper describes overnight closed-loop control with the Florence automated system with model predictive control algorithm in 16 adolescents for 3 weeks at home.
• Nimri R, Muller I, Atlas E, et al. MD-Logic Overnight control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover trial. Diabetes Care. 2014;37:3025–32. Describes use of the MD‐Logic system in overnight closed‐loop control in 24 patients for 6 weeks at home.
Elleri D, Allen JM, Kumareswaran K, et al. Closed-loop basal insulin delivery over 36 hours in adolescents with type 1 diabetes: randomized clinical trial. Diabetes Care. 2012;36:838–44.
• Kovatchev BP, Renard E, Cobelli C, et al. Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas. Diabetes Care. 2014;37:1789–96. Describes the use of the DIAS system for day and night closed‐loop control in 18 adults for 40 hours in outpatient setting.
•• Leelarathna L, Dellweg S, Mader JK, et al. Day and night home closed-loop insulin delivery in adults with type 1 diabetes: three-center randomized crossover study. Diabetes Care 2014;37:1931–7. Report from the AP@home consortium of day and night closed‐loop control with the Cambridge algorithm for 7 days at home in 17 adults.
• Russell SJ, El-Khatib FH, Sinha M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med. 2014;371:313–25. Closed-loop control using a bihormonal approach infusing both insulin and glucagon in both adults (n = 20) and adolescents (n = 32) with type 1 diabetes over 5 days.
Disclosure
Trang T. Ly has received speaker honorarium from Medtronic Diabetes. Bruce A. Buckingham has a patent pending and has received payment for board membership from Animas, BD, and Convatec.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Topical Collection on Endocrine.
Rights and permissions
About this article
Cite this article
Ly, T.T., Buckingham, B.A. Technology and Type 1 Diabetes: Closed-Loop Therapies. Curr Pediatr Rep 3, 170–176 (2015). https://doi.org/10.1007/s40124-015-0083-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40124-015-0083-y